# US 2003/0073149 A1 · Antibody complexes and methods for immunolabeling

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0073149 A1
- Document ID: US20030073149A1
- Status: Published application
- Kind: A1
- Application number: 10/118,204
- Filed: 2002-04-05
- Published: 2003-04-17
- Earliest claimed: 2001-10-12
- Assignees: Life Technologies Corporation
- Inventors: Robert A. Archer; Joseph M. Beechem; David C. Hagen; Richard P. Haugland; Rosaria Haugland
- Web page: https://patentgrep.com/patent/US20030073149A1

## CPC

- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- B82Y 10/00: Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
- B82Y 30/00: Nanotechnology for materials or surface science, e.g. nanocomposites
- G01N 33/58: involving labelled substances (G01N33/53 takes precedence)
- G01N 33/6857: {Antibody fragments}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

The present invention provides novel immunolabeling complexes and certain components of such complexes, as well as methods of preparing and using such complexes, and kits for use in preparing labeling proteins and for immunolabeling. The pre-formed immunolabeling complexes of the invention comprise both a target-binding antibody and a labeling protein that contains covalently attached labels, where the labeling protein binds selectively and with high affinity to a selected region of the target-binding antibody. Novel labeling proteins of the invention include non-antibody peptides and proteins, such as a complex of protein G and a labeled albumin, and monovalent antibody fragments, such as labeled Fab fragments of an anti-Fc antibody. In methods of the invention, the preformed immunolabeling complexes are added to the sample alone or in combination, for purposes of labeling and optionally detecting the target of interest.

## Claims

### Claim 1

A method for determining the presence of a desired target in a biological sample, said method comprising:
a) combining an immunolabeling mixture with said sample wherein said immunolabeling mixture comprises a target-binding antibody bound to a labeling protein, wherein said labeling protein comprises a monovalent antibody fragment or a non-antibody peptide or protein, wherein said labeling protein is covalently linked to one or more labels; and
b) detecting the presence or absence of said label whereby the presence or absence of said target is determined.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said labeling mixture contains at least one target-binding antibody bound by said labeling protein wherein said target-binding antibody is a single chain fragment variable, and said labeling protein binds selectively and with high affinity to a selected peptide linker region of the target-binding antibody.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the labeling mixture contains two or more target-binding antibodies bound by labeling proteins, wherein one of said target-binding antibodies is bound by a first labeling protein and another said target-binding antibody is bound by a second labeling protein.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said target-binding antibody has two or more different labeling proteins bound to the antibody and at least one labeling protein is detectably distinct from other labeling proteins.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said non-antibody protein is selected from the group consisting of a protein G, a protein A, a protein L, a lectin, and a protein G bound to albumin, wherein said albumin is covalently linked to one or more labels and albumin is selected from the group consisting of human albumin, bovine serum albumin, and ovalbumin.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said monovalent antibody fragment is a Fab or Fab′ fragment and is selected from the group consisting of anti-Fc antibody fragment, anti-kappa light chain antibody fragment, anti-lambda light chain antibody fragment, and a single chain variable protein fragment.

### Claim 7 (depends on 6)

The method according to claim 6, wherein said antibody fragment is derived from a monoclonal antibody or polyclonal antibody.

### Claim 8 (depends on 7)

The method according to claim 7, wherein said polyclonal antibody is a rabbit or a goat polyclonal antibody.

### Claim 9 (depends on 7)

The method according to claim 7, wherein said monoclonal antibody is classified as mouse IgM, IgG1, IgG2a, IgG2b, or IgG3 antibody, or an equivalent thereof.

### Claim 10 (depends on 1)

The method according to claim 1, wherein said label is selected from the group consisting of a fluorescent dye, a phosphorescent dye, a tandem dye, a particle, an electron transfer agent, biotin and a radioisotope.

### Claim 11 (depends on 10)

The method according to claim 10, wherein said fluorescent dye is selected from the group consisting of a fluorescent sulfonated xanthene dye, a fluorescent sulfonated cyanine dye, and a fluorescent phycobiliprotein dye.

### Claim 12 (depends on 10)

The method according to claim 10, wherein said tandem dye is selected from the group consisting of sulfonated cyanine-phycobiliprotein tandem dye and sulfonated xanthene-phycobiliprotein tandem dye.

### Claim 13 (depends on 1)

The method according to claim 1, wherein said biological sample comprises eukaryotic or prokaryotic cells, cellular extract, subcellular component, tissue culture, tissue, a bodily fluid, or a portion or combination thereof.

### Claim 14 (depends on 1, 13)

The method according to claim 1, wherein said target-binding antibody binds to an antigenic determinate present in the biological sample of claim 13.

### Claim 15 (depends on 13)

The method according to claim 13, wherein said sample is immobilized on a surface.

### Claim 16 (depends on 13)

The method according to claim 13, wherein said sample is in a gel or on a blot or in an array.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the amount of target-binding antibody is about 5 micrograms to about 0.001 micrograms.

### Claim 18 (depends on 1)

The method according to claim 1, further comprising binding of unbound labeling protein prior to combining labeling mixture with sample, wherein a capture component is added to the labeling mixture and binding said unbound labeling protein.

### Claim 19 (depends on 18)

The method of claim 18, wherein said capture component is an antibody or an antibody fragment, and is optionally attached to a microsphere or to agarose.

### Claim 20 (depends on 1)

The method according to claim 1, wherein said labeling mixture contains at least one target-binding antibody bound to a labeling protein and
i) the labeling protein is a fragment of a rabbit or goat polyclonal antibody or of a mouse IgG1, IgG2a, IgG2b, IgG3 antibody,
ii) the labeling protein is an anti-Fc antibody fragment that is a monovalent Fab or Fab′ fragment, wherein the labeling protein is covalently labeled with one or more labels that are selected from the group consisting of fluorescent sulfonated xanthene dye, fluorescent sulfonated cyanine dye, fluorescent phycobiliprotein dye, sulfonated cyanine-phycobiliprotein tandem dye, and sulfonated xanthene-phycobiliprotein tandem dye, which labels are optionally the same or different; and
the capture component is an antibody or an antibody fragment, which is optionally attached to a microsphere or to agarose.

### Claim 21

A method for determining the presence of a desired target in a biological sample, said method comprising:
a) combining an immunolabeling mixture with said sample wherein said immunolabeling mixture comprises a first target-binding antibody bound to a first labeling protein and a second target-binding antibody bound to a second labeling protein, wherein said first and second labeling proteins comprise a monovalent antibody fragment or a non-antibody peptide or protein that are detectably distinct, and wherein said labeling proteins are covalently linked to one or more labels; and
b) detecting the presence or absence of said labels whereby the presence or absence of said target is determined.

### Claim 22 (depends on 21)

The method according to claim 21, wherein said first labeling protein is a non-antibody peptide or protein and said second labeling protein is a non-antibody peptide or protein.

### Claim 24 (depends on 22)

The method according to claim 22, wherein said first and second non-antibody proteins are independently selected from the group consisting of a protein G, a protein A, a protein L, a lectin, and a G protein bound to albumin, wherein said albumin is covalently linked to one or more labels and albumin is selected from the group consisting of human albumin, bovine serum albumin, and ovalbumin.

### Claim 25 (depends on 21)

The method of claim 21, wherein said first labeling protein is a first monovalent antibody fragment and said second labeling protein is a second monovalent antibody fragment.

### Claim 26 (depends on 25)

The method according to claim 25, wherein said first and second monovalent antibody fragments are independently Fab or Fab′ fragments and are selected from the group consisting of anti-Fc antibody fragment, anti-kappa light chain antibody fragment, anti-lambda light chain antibody fragment, and a single chain variable protein fragment.

### Claim 27 (depends on 25)

The method according to claim 25, wherein said first and second antibody fragments are derived from a monoclonal antibody or polyclonal antibody.

### Claim 28 (depends on 27)

The method according to claim 27, wherein said polyclonal antibody is a rabbit or a goat polyclonal antibody.

### Claim 29 (depends on 27)

The method according to claim 27, wherein said monoclonal antibody is classified as mouse IgM, IgG1, IgG2a, IgG2b, or IgG3 antibody, or an equivalent thereof.

### Claim 30 (depends on 21)

The method according to claim 21, wherein said labels are selected from the group consisting of a fluorescent dye, a phosphorescent dye, a tandem dye, a particle, an electron transfer agent, biotin and a radioisotope.

### Claim 31 (depends on 30)

The method according to claim 30, wherein said fluorescent dye is selected from the group consisting of a fluorescent sulfonated xanthene dye, a fluorescent sulfonated cyanine dye, and a fluorescent phycobiliprotein dye.

### Claim 32 (depends on 30)

The method according to claim 30, wherein said tandem dye is selected from the group consisting of sulfonated cyanine-phycobiliprotein tandem dye and sulfonated xanthene-phycobiliprotein tandem dye.

### Claim 33 (depends on 21)

The method according to claim 21, wherein said biological sample comprises eukaryotic or prokaryotic cells, cellular extract, subcellular component, tissue culture, tissue, a bodily fluid, or a portion or combination thereof.

### Claim 34 (depends on 33)

The method according to claim 33, wherein said target-binding antibody binds to an antigenic determinate present in said biological sample.

### Claim 35 (depends on 34)

The method according to claim 34, wherein the amount of target-binding antibody is about 5 micrograms to about 0.001 micrograms.

### Claim 36 (depends on 21)

The method of claim 21, wherein said sample is immobilized on a solid surface.

### Claim 37 (depends on 21)

The method of claim 21, wherein said sample is in a gel, or on a blot or in an array.

### Claim 38 (depends on 21)

The method according to claim 21, further comprising binding of unbound labeling protein prior to combining labeling mixture with sample, wherein a capture component is added to the labeling mixture binding said unbound labeling protein.

### Claim 39 (depends on 38)

The method of claim 38, wherein said capture component is an antibody or an antibody fragment, and is optionally attached to a microsphere or to agarose.

### Claim 40 (depends on 21)

A method according to claim 21 wherein said labeling mixture contains at least two target-binding antibodies each bound by at least one labeling protein; and
a) said first and second labeling proteins are independently a fragment of a rabbit or goat polyclonal antibody or a mouse IgG1, IgG2a, IgG2b, IgG3 antibody,
b) said first and second labeling proteins are an anti-Fc antibody fragment that is a monovalent Fab or Fab′ fragment, wherein said first and second labeling proteins are covalently labeled with one or more labels that are independently selected from the group consisting of fluorescent sulfonated xanthene dye, fluorescent sulfonated cyanine dye, fluorescent phycobiliprotein dye, sulfonated cyanine-phycobiliprotein tandem dye, and sulfonated xanthene-phycobiliprotein tandem dye, which labels are optionally the same or different; and
the capture component is an antibody or an antibody fragment, which is optionally attached to a microsphere or to agarose.

### Claim 41

A method for determining the presence of a desired target in a biological sample, said method comprising:
a) combining an immunolabeling mixture with said sample wherein said immunolabeling mixture comprises a target-binding antibody bound to a labeling protein, wherein said labeling protein comprises a monovalent antibody fragment or a non-antibody peptide or protein, and wherein said labeling protein is covalently linked to one or more labels; and
b) adding an enzymatic substrate, which is selected from the group consisting of a chromogenic, a fluorogenic and chemiluminescent substrate to the sample combined with said immunolabeled mixture; and
c) detecting the presence or absence of said label whereby the presence or absence of said target is determined.

### Claim 42 (depends on 41)

The method according to claim 41, wherein said substrate is a peroxidase substrate, a luciferase substrate, a phosphatase substrate, a glycosidase substrate or a luciferase substrate..

### Claim 43 (depends on 42)

The method according to claim 42, wherein said substrate is activated by an enzyme, which is selected from the group consisting of peroxidase, phosphatase, glycosidase, and luciferase.

### Claim 44 (depends on 43)

The method according to claim 43, wherein said peroxidase is horseradish peroxidase, Coprinus cinereus peroxidase, or Arthromyces ramosus peroxidase.

### Claim 45 (depends on 43)

The method according to claim 43, wherein said phosphatase is alkaline phosphatase.

### Claim 46 (depends on 43)

The method according to claim 43, wherein said glycosidase is β-galactosidase or β-glucuronidase.

### Claim 47 (depends on 43)

The method according to claim 43, wherein said luciferase is protein A luciferase or protein G luciferase.

### Claim 48

An isolated immunolabeling complex consisting essentially of:
a target-binding antibody bound by one or more labeling proteins that is a non-antibody peptide or protein, or a monovalent antibody fragment, wherein said labeling protein(s) bind selectively and with high affinity to a selected region of the target-binding antibody, and wherein said labeling protein is covalently linked to one or more labels.

### Claim 49 (depends on 48)

The immunolabeling complex according to claim 48, wherein at least one labeling protein is detectably distinct from the other labeling proteins.

### Claim 50

An isolated immunolabeling complex consisting essentially of:
a target-binding antibody bound by one or more monovalent labeling proteins that is a non-antibody immunoglobulin-binding peptide or protein, or is a monovalent antibody fragment, wherein said labeling protein binds selectively and with high affinity to a selected region of the target-binding antibody, and where each labeling protein is covalently labeled with an enzyme.

### Claim 51

An isolated immunolabeling complex consisting essentially of:
a target-binding antibody bound by one or more monovalent labeling proteins that is a non-antibody immunoglobulin-binding peptide or protein, or is a monovalent antibody fragment, wherein said labeling protein binds selectively and with high affinity to a selected region of the target-binding antibody, and where each labeling protein is covalently labeled with a hapten.

### Claim 52

An isolated monovalent labeling protein consisting essentially of a monovalent fragment generated from an antibody and capable of binding selectively and with high affinity to a selected region of a second antibody, wherein said monovalent protein is covalently labeled with one or more labels, and which labels are optionally the same or different.

### Claim 53

An isolated labeling mixture comprising one or more immunolabeling complexes, wherein at least one immunolabeling complex consists essentially of:
a target-binding antibody bound by a labeling protein, that is a non-antibody peptide or protein, or is a monovalent antibody fragment, wherein said labeling protein binds selectively and with high affinity to a selected region of the target-binding antibody, and the labeling protein is covalently labeled with one or more labels, which labels are optionally the same or different.

### Claim 54 (depends on 53)

The isolated labeling mixture according to claim 53, further comprising a capture component that is an antibody or antibody fragment and is optionally attached to a microsphere or to agarose.

### Claim 55

An isolated labeling mixture comprising one or more immunolabeling complexes, wherein at least one immunolabeling complex consist essentially of a target-binding antibody bound by a labeling protein that is a protein G complexed with albumin, wherein said albumin is covalently labeled with one or more labels, and which labels are optionally the same or different.

### Claim 56 (depends on 55)

The isolated labeling mixture according to claim 55, wherein said albumin is human albumin, bovine serum albumin, or ovalbumin.

### Claim 57

An isolated protein G complex consisting essentially of protein G and albumin, wherein said albumin is covalently labeled with one or more labels, which labels are optionally the same or different.

### Claim 58 (depends on 57)

The isolated protein G complex according to claim 57, wherein said albumin is human albumin, bovine serum albumin, or ovalbumin.

### Claim 59

A kit for preparing an immunolabeling complex, said kit comprising:
a) a labeling mixture consisting essentially of one or more monovalent antibody fragments that bind selectively and with high affinity to a specific region of one or more target-binding antibodies, where each fragment is covalently labeled with one or more labels, and which said labels are optionally the same or different and a capture component to which the antibody fragments bind, that is optionally attached to a microsphere or to agarose.

### Claim 60

A kit for preparing an immunolabeling complex, said kit comprising:
a) a protein G complex with albumin, wherein said albumin is covalently labeled with one or more labels, and which labels are optionally the same or different; and
b) a capture component to which the protein G complexed with albumin binds, wherein said capture component is optionally attached to a microsphere or to agarose.

### Claim 61

A kit for immunolabeling a desired target in a biological sample, said kit comprising:
a) a labeling mixture of one or more immunolabeling complexes, wherein at least one immunolabeling complex comprises a target-binding antibody bound by a protein G complexed with albumin, wherein said albumin is covalently labeled with one or more labels, and which detectable moieties are optionally the same or different; and
b) a buffer.

### Claim 62 (depends on 61)

The kit according to claim 61, wherein said albumin is human albumin, bovine serum albumin, or ovalbumin.

### Claim 63

A kit for immunolabeling a target in a sample, said kit comprising:
a) a labeling mixture of one or more immunolabeling complexes, wherein at least one immunolabeling complex comprises a target-binding antibody bound by a labeling protein that is a non-antibody peptide or protein, or a monovalent antibody fragment, wherein said labeling protein binds selectively and with high affinity to a selected region of the target-binding antibody, and where the labeling protein is covalently labeled with one or more labels, which directly detectable moieties are optionally the same or different; and
b) a buffer.

### Claim 64

An isolated monovalent fragment for labeling antibodies made by the process comprising the steps of:
a) generating a labeling antibody against an antigen, where said antigen is a Fc region of an antibody from a different species;
b) digesting said labeling antibody to generate multiple monovalent fragments;
c) covalently labeling said monovalent fragments with one or more labels, where said labels on each monovalent fragment are optionally the same or different; and
d) isolating said monovalent fragments before or after covalent labeling.

### Claim 65 (depends on 64)

The isolated monovalent fragment for labeling target-binding antibodies made by the process according to claim 64, wherein said species is selected from the group consisting of mouse, rabbit and goat.

### Claim 66 (depends on 64)

The isolated monovalent fragment for labeling target-binding antibodies made by the process according to claim 64, wherein said labeling antibody is digested with papain to yield multiple Fab fragments.

### Claim 67 (depends on 64)

The isolated monovalent fragment for labeling target-binding antibodies made by the process according to claim 64, wherein said fragments are covalently labeled with one or more directly detectable fluorescent dyes, phosphorescent dyes, dye tandems, fluorescent proteins, particles, or electron transfer agents, or combinations thereof.

### Claim 68 (depends on 64)

The isolated monovalent fragment for labeling target-binding antibodies made by the process according to claim 64, wherein;
a) before said fragments are covalently labeled, said fragments are immobilized by binding to one or more complementary antibodies, where such binding protects the binding region of such fragments;
b) after said fragments are covalently labeled, isolating said monovalent fragments by dissociating such fragments from such complementary antibodies.

### Claim 69

An isolated monovalent fragment for labeling target-binding antibodies made by the process comprising the steps of:
a) generating a labeling antibody against an antigen, where said antigen is a selected peptide linker region of a single-chain variable protein fragment;
b) digesting said labeling antibody to generate multiple monovalent fragments;
c) covalently labeling said monovalent fragments with one or more labels, where said labels on each monovalent fragment are optionally the same or different; and
d) isolating said monovalent fragments before or after covalent labeling.

### Claim 70

An isolated immunolabeling complex made by a process comprising:
a) combining, in vitro, one or more target-binding antibodies with an amount of labeling protein in excess of a ratio of at least one labeling protein to each target-binding antibody, under conditions suitable for the labeling protein to bind to the target-binding antibodies, and where each labeling protein is a non-antibody peptide or protein, or is a monovalent antibody fragment, wherein said labeling protein binds selectively and with high affinity to a selected region of said target-binding antibody to form an immunolabeling complex, and each labeling protein is covalently labeled with one or more labels, where the said labels on each labeling protein are optionally the same or different;
b) isolating said immunolabeling complex after said labeling protein binds to the target-binding antibodies.

### Claim 71 (depends on 70)

The isolated immunolabeling complex made by the process according to claim 70, wherein said target-binding antibodies that are combined with the labeling protein are present in a heterogeneous protein mixture.

### Claim 72 (depends on 70)

The isolated immunolabeling complex made by the process according to claim 70, wherein said heterogeneous protein mixture is ascites fluid or hybridoma culture supernatant.

### Claim 73 (depends on 70)

The isolated immunolabeling complex made by the process according to claim 70, wherein said labeling protein is in excess of a ratio of 3 moles of labeling protein for each mole of target-binding antibody.

### Claim 74 (depends on 70)

The isolated immunolabeling complex made by the process according to claim 70, wherein at least one labeling protein is a monovalent antibody fragment, and said monovalent fragment is covalently labeled with one or more fluorescent dyes, chemiluminescent dyes, tandem dyes, fluorescent proteins, or combinations thereof.

### Claim 75 (depends on 70)

The isolated immunolabeling complex made by the process according to claim 70, wherein said target-binding antibody binds to an antigenic determinate present in a biological sample.

### Claim 76 (depends on 70)

The isolated immunolabeling complex made by the process according to claim 70, wherein at least one labeling protein is a monovalent fragment that has been made by the process consisting essentially of:
a) generating a labeling antibody against an antigen, where said antigen is a Fc region of an antibody from a different species;
b) digesting said labeling antibody to generate multiple monovalent fragments;
c) covalently labeling said monovalent fragments with one or more labels, where said labels on each monovalent fragment are optionally the same or different; and
d) isolating said monovalent fragments before or after covalent labeling.

### Claim 77 (depends on 76)

The isolated monovalent fragment made by the process according to claim 76, wherein said labeling protein that is not bound to the target-binding antibodies are bound to a capture component, which is optionally attached to a microsphere or to agarose.

### Claim 78 (depends on 76)

The monovalent fragment made by the process according to claim 76, wherein the step of covalently labeling said monovalent fragments is accomplished by immobilizing said monovalent fragments by binding to one or more complementary antibodies, where such binding protects the binding region of such fragments; and
wherein the step of isolating said monovalent fragments is accomplished by dissociating such fragments from such complementary antibodies after covalent labeling.

### Claim 79 (depends on 76)

The isolated monovalent fragment made by the process according to claim 76, wherein said species is selected from the group consisting of mouse, rabbit or goat.

### Claim 80 (depends on 76)

The isolated monovalent fragment made by the process according to claim 76, wherein said labeling antibody is digested with papain to yield multiple Fab fragments.

### Claim 81 (depends on 70)

The isolated immunolabeling complex made by the process according to claim 70, wherein the target-binding antibody is a single-chain variable protein fragment wherein at least one labeling protein is a monovalent fragment that has been made by the process consisting essentially of:
a) generating a labeling antibody against an antigen, wherein said antigen is a selected peptide linker region of said single-chain variable protein fragment;
b) digesting said labeling antibody to generate multiple monovalent fragments;
c) covalently labeling said monovalent fragments with one or more labels, where said labels on each monovalent fragment are optionally the same or different; and
d) isolating said monovalent fragments before or after covalent labeling.

### Claim 82 (depends on 81)

The isolated monovalent fragment for labeling antibodies made by the process according to claim 81, wherein said labeling antibody is digested with papain to yield multiple Fab fragments.

### Claim 83 (depends on 1)

A method according to claim 1, further comprising stabilizing binding of said target-binding antibody to said labeling protein.

### Claim 84

A kit for preparing labeling proteins, said kit comprising:
a) a monovalent antibody fragment that binds selectively and with high affinity to a specific region of one or more target-binding antibodies,
b) a chemically reactive dye; and
c) an immobilization matrix comprising the binding domain of the labeling protein.
